ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Buckland
|
58 |
13K |
2 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
58
|
13K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Buckland
|
58 |
13K |
0 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
58
|
13K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Buckland
|
58 |
13K |
3 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
58
|
13K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Buckland
|
58 |
13K |
8 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
58
|
13K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Buckland
|
227 |
52K |
4 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
227
|
52K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Buckland
|
227 |
52K |
3 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
227
|
52K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Walk to Defeat MND
|
|
Buckland
|
32 |
9.3K |
2 |
05/05/24 |
05/05/24 |
ASX - By Stock
|
32
|
9.3K
|
2
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Buckland
|
133 |
40K |
0 |
05/05/24 |
05/05/24 |
ASX - By Stock
|
133
|
40K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Walk to Defeat MND
|
|
Buckland
|
32 |
9.3K |
4 |
05/05/24 |
05/05/24 |
ASX - By Stock
|
32
|
9.3K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Buckland
|
227 |
52K |
8 |
05/05/24 |
05/05/24 |
ASX - By Stock
|
227
|
52K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Buckland
|
227 |
52K |
14 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
227
|
52K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
1 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
18K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Buckland
|
227 |
52K |
12 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
227
|
52K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
0 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
104
|
18K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
1.3K
|
332K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
1.3K
|
332K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
2 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
1.3K
|
332K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
4 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
1.3K
|
332K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
4 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
18K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.3K
|
332K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
3 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
18K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
4 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
261
|
66K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
2 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
261
|
66K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
7 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Buckland
|
104 |
18K |
11 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
104
|
18K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
6 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
2 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
3 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
3
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Buckland
|
133 |
40K |
1 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
133
|
40K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
1 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
4 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
4
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Buckland
|
133 |
40K |
7 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
133
|
40K
|
7
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Buckland
|
133 |
40K |
2 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
133
|
40K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
2 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
261
|
66K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
3 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
261
|
66K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
7 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
66K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
66K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
66K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Buckland
|
261 |
66K |
8 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
66K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Resignation of CEO
|
|
Buckland
|
4 |
1.4K |
3 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
Buckland
|
100 |
26K |
3 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
100
|
26K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
3 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
0 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
3 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Buckland
|
1.3K |
332K |
1 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.3K
|
332K
|
1
|
|